Integrative genomics identifies the molecular basis of resistance to azacitidine therapy in myelodysplastic syndromes
Myelodysplastic syndromes and chronic myelomonocytic leukemia are blood disorders characterized by ineffective hematopoiesis and progressive marrow failure that can transform into acute leukemia. The DNA methyltransferase inhibitor 5-azacytidine (AZA) is the most effective pharmacological option, bu...
Κύριοι συγγραφείς: | Unnikrishnan, A, Deshpande, NP, Verma, A, Kumari, A, Richards, LA, Knezevic, K, Chandrakanthan, V, Thoms, JAI, Tursky, ML, Huang, Y, Ali, Z, Olivier, J, Galbraith, S, Kulasekararaj, AG, Tobiasson, M, Karimi, M, Pellagatti, A, Wilson, SR, Lindeman, R, Young, B, Ramakrishna, R, Arthur, C, Stark, R, Crispin, P, Curnow, J, Warburton, P, Roncolato, F, Boultwood, J, Lynch, K, Jacobsen, SEW, Mufti, GJ, Hellstrom-Lindberg, E, Wilkins, MR, MacKenzie, KL, Wong, JWH, Campbell, PJ, Pimanda, JE |
---|---|
Μορφή: | Journal article |
Γλώσσα: | English |
Έκδοση: |
Cell Press
2017
|
Παρόμοια τεκμήρια
Παρόμοια τεκμήρια
-
Myelodysplastic syndromes: moving towards personalized management
ανά: Eva Hellström-Lindberg, κ.ά.
Έκδοση: (2020-07-01) -
Spliceosome mutations: 1 plus 1 does not always equal 2
ανά: Pellagatti, A, κ.ά.
Έκδοση: (2020) -
Reduced translation of GATA1 in Diamond-Blackfan anemia.
ανά: Boultwood, J, κ.ά.
Έκδοση: (2014) -
SF3B1 mutant myelodysplastic syndrome: Recent advances
ανά: Pellagatti, A, κ.ά.
Έκδοση: (2020) -
Splicing factor gene mutations in the myelodysplastic syndromes: impact on disease phenotype and therapeutic applications.
ανά: Pellagatti, A, κ.ά.
Έκδοση: (2016)